• Lawyers
  • Practices
  • COVID-19 Resources
  • Insights
    • Firm News
    • Press Releases
    • Publications
    • Webcasts
    • Subscribe
    • Media Contacts
  • Careers
    • Career Opportunities
    • Attorney Development
    • Contact Us
  • About
    • Our Story
    • Awards & Accolades
    • Offices
    • Diversity
    • Pro Bono
    • Alumni
    • Contact Us
  • Biography
  • Education
  • Recent Publications
Profile Picture

Sean S. Twomey

Sean
Twomey

Associate Attorney

CONTACT INFO

stwomey@gibsondunn.com

TEL:+1 213.229.7284

FAX:+1 213.229.6284

Los Angeles

333 South Grand Avenue, Los Angeles, CA 90071-3197 USA

  • Print
  • |
  • Share
  • |
  • vCard

PRACTICE

FDA and Health Care Appellate and Constitutional Law FCPA False Claims Act/Qui Tam Defense Government Contracts Life Sciences Litigation Sports Law White Collar Defense and Investigations

BIOGRAPHY

Sean S. Twomey is a litigation associate in the Los Angeles office of Gibson, Dunn & Crutcher LLP.  His practice focuses on complex commercial cases, appellate law, sports law, and health care compliance, enforcement, and litigation.  Mr. Twomey has represented clients in the pharmaceutical, health care, defense, athletic apparel, and sports marketing industries, including Nike, Allergan, Lockheed Martin, Microsemi, and the Gatorade Company in contract disputes, securities litigation, and business tort, patent, trade secret, and unfair competition matters.

Mr. Twomey’s experience also includes advising clients regarding high-profile athlete endorsement contract negotiations.  In addition, he has experience handling internal investigations, compliance audits, False Claims Act qui tam litigation, and civil and criminal investigations and enforcement actions relating to export controls, off-label promotion, anti-kickback issues, and drug and device advertising, design, and safety issues.

Representative Matters Include:

  • Havensight Capital LLC v. Nike, Inc., 891 F.3d 1167 (9th Cir. 2018).  Obtained dismissal with prejudice and Rule 11 sanctions in a lawsuit seeking $600 million in damages from Nike for antitrust, business tort, racketeering, and unfair competition claims based on alleged anticompetitive conduct.  On appeal, the Ninth Circuit affirmed the district court’s award of sanctions and declined to review the district court’s dismissal for lack of jurisdiction.
  • Nike, Inc. v. Dekovic, et. al., 2014 WL 12663761 (Or. 2014).  Obtained a temporary restraining order and preliminary injunction on behalf of Nike in misappropriation of trade secret, breach of contract, and business tort litigation involving adidas and three former Nike footwear designers, ultimately securing a confidential settlement following favorable discovery rulings.
  • Oakley, Inc. v. Nike, Inc., and Rory McIlroy, 988 F.Supp.2d 1130 (C.D. Cal. 2013).  Obtained summary judgment on behalf of Nike in a breach of contract and business tort lawsuit in which Oakley sought over $100 million in damages from Nike and professional golfer Rory McIlroy after Mr. McIlroy signed an endorsement agreement with Nike.
  • United States ex rel. McGrath v. Microsemi Corp., 140 F. Supp. 3d 885 (D. Ariz. 2015), aff’d 690 Fed.App’x. 551 (9th Cir. 2017).  Obtained dismissal at the pleadings stage of a False Claims Act suit seeking over $2 billion from Microsemi based on alleged noncompliance with export control regulations.  On appeal, the Ninth Circuit affirmed the district court’s dismissal with prejudice and the Supreme Court denied certiorari.
  • Miotox LLC v. Allergan, Inc., 2015 WL 2084493, 2015 WL 5838465 (C.D. Cal. 2015).  Defeated a motion to dismiss patent counterclaims and obtained summary judgment in Allergan’s favor on breach of patent license agreement claims in which licensor sought $600 million in damages.
  • Allergan, Inc., et. al. v Athena Cosmetics, Inc., et. al., 738 F.3d 1350 (Fed. Cir. 2013).  Obtained summary judgment and a permanent injunction on behalf of Allergan in consolidated patent and unfair competition claims against several entities unlawfully selling eyelash growth drugs in competition with Allergan.  On appeal, the Federal Circuit affirmed the district court’s summary judgment and injunction rulings, with a modification to the geographic scope of the injunction.
  • Defending pharmaceutical and medical device manufacturers in False Claims Act qui tam lawsuits, and civil and criminal investigations by the U.S. Department of Justice, the Office of Inspector General of the Department of Health and Human Services, and state Attorney Generals.

In addition, Mr. Twomey frequently practices before both the United States Court of Appeals for Veterans Claims and the United States Department of Veterans Affairs, representing U.S. veterans on a pro bono basis in claims for service-connected medical benefits.  Mr. Twomey also supervises law students handling veteran’s benefits appeals through pro bono programs at the University of California at Irvine School of Law and the University of Virginia School of Law.

Mr. Twomey graduated Order of the Coif from the University of Virginia School of Law, where he was also awarded the Paul A. Simon Memorial Scholarship and the Pro Bono Service Award.  In law school, Mr. Twomey served as Executive Editor of the Virginia Journal of Law & Social Policy.  He graduated summa cum laude from the University of California at Los Angeles in 2007, with a Bachelor of Arts degree in Philosophy.

Mr. Twomey is a member of the bars of the State of California, the District of Columbia, and the State of New York.  He is also admitted to practice before the United States Courts of Appeals for the Ninth Circuit and Federal Circuit, and the United States District Courts for the Central, Northern, and Southern Districts of California.

EDUCATION

University of Virginia - 2011 Juris Doctor

University of California - Los Angeles - 2007 Bachelor of Arts

ADMISSIONS

California Bar

District of Columbia Bar

New York Bar

RECENT PUBLICATIONS

Client Alert - January 27, 2021 | 2020 Year-End False Claims Act Update
Client Alert - July 17, 2020 | 2020 Mid-Year False Claims Act Update
Client Alert - April 1, 2020 | Implications of COVID-19 Crisis for False Claims Act Compliance
Publications - February 27, 2020 | False Claims Act Enforcement Under the Trump Administration
Client Alert - January 31, 2020 | 2019 Year-End False Claims Act Update
Client Alert - November 5, 2019 | U.S. Department of Justice and U.S. Department of Housing and Urban Development Issue Memorandum on Application of the False Claims Act
Webcasts - September 18, 2019 | Webcast: The False Claims Act – 2019 Mid-Year Update: Financial Services Sector
Publications - August 6, 2019 | Mid-Year Review: False Claims Act Enforcement in 2019
Client Alert - July 16, 2019 | 2019 Mid-Year False Claims Act Update
Publications - February 14, 2019 | Looking back and ahead at the False Claims Act
Client Alert - February 13, 2019 | 2018 Year-End FDA and Health Care Compliance and Enforcement Update – Drugs and Devices
Client Alert - January 10, 2019 | 2018 Year-End False Claims Act Update
Client Alert - July 12, 2018 | 2018 Mid-Year False Claims Act Update
Client Alert - January 24, 2018 | 2017 Year-End FDA and Health Care Compliance and Enforcement Update – Drugs and Devices
Client Alert - January 5, 2018 | 2017 Year-End False Claims Act Update
Client Alert - August 25, 2017 | 2017 Mid-Year FDA and Health Care Compliance and Enforcement Update – Drugs and Devices
Client Alert - July 12, 2017 | 2017 Mid-Year False Claims Act Update
Client Alert - January 12, 2017 | 2016 Year-End FDA and Health Care Compliance and Enforcement Update – Drugs and Devices
Client Alert - January 5, 2017 | 2016 Year-End False Claims Act Update
Client Alert - July 27, 2016 | 2016 Mid-Year FDA and Health Care Compliance and Enforcement Update – Drugs and Devices
Client Alert - July 7, 2016 | 2016 Mid-Year False Claims Act Update
Client Alert - January 19, 2016 | 2015 Year-End FDA and Health Care Compliance and Enforcement Update – Drugs and Devices
Client Alert - January 6, 2016 | 2015 Year-End False Claims Act Update
Client Alert - July 8, 2015 | 2015 Mid-Year False Claims Act Update
Client Alert - January 14, 2015 | 2014 Year-End Health Care Compliance and Enforcement Update – Providers
Client Alert - January 14, 2015 | 2014 Year-End FDA and Health Care Compliance and Enforcement Update – Drugs and Devices
Client Alert - January 7, 2015 | 2014 Year-End False Claims Act Update
Client Alert - March 23, 2012 | U.S. Supreme Court Allows Pre-Enforcement Review of Administrative Compliance Orders Issued by EPA Under the Clean Water Act
  • Sitemap
  • Client Extranet
  • Legal Notices
  • Privacy Policy
  • Cookie Notice
  • Contact Us
©Gibson, Dunn & Crutcher LLP 2021. All rights reserved.
Top
This website uses cookies to provide analytics on user traffic. By continuing to browse our website, you consent to our use of cookies as set forth in our Cookie Policy. However you may visit Cookie Settings to customize your consent.
Cookie SettingsACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.

Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Analytics

Cookies that tie into analytics systems, such as Google Analytics, YouTube and Vimeo analytics for embedded video, etc. The following are the cookies installed by the service: _ga, _gid, collect, vuid

Performance

These cookies collect information about how visitors use a website, for instance which pages visitors go to most often, and if they get error messages from web pages. These cookies don’t collect information that identifies a visitor. All information these cookies collect is aggregated and therefore anonymous. It is only used to improve how a website works. The following cookie is installed by the Google Analytics service: _gat

Save & Accept